The COVID MyStudies app enables the investigator to send the electronic informed consent document directly to the subject or authorized representative. The subject receives an electronic copy after signing the document. (FDA regulations require the subject to be provided with a copy of the informed consent, and FDA prefers that it be the signed copy.) The investigator can also access the signed consent document electronically and can print or transfer it electronically.
While FDA has not made clear what trial types are eligible for use with the app, the app appears to be aimed at IND studies. FDA directs interested investigators to email CDER at CDERMedicalPolicy-RealWorldEvidence@fda.hhs.gov and to include their pre-IND or IND number if applicable. The Harvard Pilgrim Health Care Institute will provide technical assistance for the app. FDA will fund this assistance “as resources permit.” We have heard that FDA has been inundated with requests and is prioritizing as quickly as possible.
FDA reminds users that the IRB must approve the informed consent process and documents. While presumably a combined informed consent form/HIPAA authorization can be submitted to the app, it is not clear whether a standalone HIPAA authorization can be executed via the app. The Mobile App Quick Overview for Research indicates that current capabilities include HIPAA-compliant data storage although users should consider whether other HIPAA obligations apply.
This contents of this alert should not be construed as legal advice or a legal opinion on any specific facts or circumstances. This content is not intended to and does not, by its receipt, create an attorney-client relationship. The contents are intended for general informational purposes only. We urge you to consult your attorney about the specific situation and any legal questions you may have. Attorney advertising in some jurisdictions. © 2023 Leibowitz Law. All rights reserved. “Leibowitz Law” is a trade name of Leibowitz LLC.
To be notified when we post new Insights, please sign up for our email list. As industry thought leaders, Leibowitz Law Insights address developing issues at the intersection of law, regulation, technology and life sciences…